外科理论与实践

外科理论与实践 >

2022 , Vol. 27 >Issue 05: 478 - 482

DOI: https://doi.org/10.16139/j.1007-9610.2022.05.019

综述

肝内胆管癌的分型和外科治疗热点

展开
  • 1. 海军军医大学第三附属医院 上海东方肝胆外科医院胆道一科，上海 200438
    2. 上海中医药大学附属普陀医院普外科，上海 200062

收稿日期: 2021-06-07

  网络出版日期: 2022-11-10

基金资助

国家自然科学基金(81972256);上海市医学重点专科建设项目(ZK2019B18);上海市普陀区临床特色专病建设项目(2020tszb03)

收起

Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment

Expand
  • 1. Department of Biliary Tract Surgery, Third Affiliated Hospital of Naval Medical University, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China
    2. Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China

Received date: 2021-06-07

  Online published: 2022-11-10

Fold

摘要

肝内胆管癌（intrahepatic cholangiocarcinoma，ICC）的分型包括形态学、病理、临床以及分子分型。目前，手术切除仍是ICC首选的治疗方式。ICC外科治疗热点涉及肝切除方式和切缘距离、淋巴结清扫、腹腔镜手术、肝移植、复发后的再手术，以及新辅助治疗和转化治疗。本文就ICC分型和外科治疗热点进行综述。

关键词： 肝内胆管癌; 外科治疗; 新辅助治疗; 转化治疗

本文引用格式

张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校 . 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022 , 27(05) : 478 -482 . DOI: 10.16139/j.1007-9610.2022.05.019

Abstract

The classification of intrahepatic cholangiocarcinoma (ICC) is based on macroscopic pattern, pathological features, clinical manifestation and molecular type. Surgical resection is still the preferred treatment for ICC. Hot topics in surgical treatment include hepatic resection procedure, distance of resection margin, lymph node dissection, laparoscopic operation, liver transplantation, reoperation after recurrence, neoadjuvant therapy and conversion therapy. The classification of ICC and hot topics in surgical treatment were focused in this review.

Key words： Intrahepatic cholangiocarcinoma; Surgical treatment; Neoadjuvant therapy; Conversion therapy

参考文献

[1] Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6):1268-1289.
[2] Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24(2):115-125.
[3] Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances[J]. Hepatology, 2019, 69(4):1803-1815.
[4] Plentz RR, Malek NP. Clinical presentation, risk factors and staging systems of cholangiocarcinoma[J]. Best Pract Res Clin Gastroenterol, 2015, 29(2):245-252.
[5] Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current know-ledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5):261-280.
[6] Lim JH, Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging fin-dings[J]. Am J Roentgenol, 2003, 181(3):819-827.
[7] Krasinskas AM. Cholangiocarcinoma[J]. Surg Pathol Clin, 2018, 11(2):403-429.
[8] Sia D, Hoshida Y, Villanueva A, et al. Integrative mole-cular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4):829-840.
[9] Rhee H, Ko JE, Chung T, et al. Transcriptomic and histopathological analysis of cholangiolocellular differen-tiation trait in intrahepatic cholangiocarcinoma[J]. Liver Int, 2018, 38(1):113-124.
[10] Si A, Li J, Yang Z, et al. Impact of anatomical versus non-anatomical liver resection on short- and long- term outcomes for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2019, 26(6):1841-1850.
[11] 吴向嵩, 陈燕, 靳云鹏, 等. 解剖性肝切除在肝内胆管癌治疗中的价值[J]. 中华外科杂志, 2018, 56(4):269-273.
[12] Li B, Song J, Aierken Y, et al. Nonanatomic resection is not inferior to anatomic resection for primary intrahepatic cholangiocarcinoma: a propensity score analysis[J]. Sci Rep, 2018, 8(1):17799.
[13] Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group[J]. Ann Surg, 2011, 254(5):824-830.
[14] Weber SM, Ribero D, O′Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement[J]. HPB (Oxford), 2015, 17(8):669-680.
[15] Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, 27(suppl 5):v28-v37.
[16] Yoh T, Cauchy F, Le Roy B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: a multicenter study[J]. Surgery, 2019, 166(6):975-982.
[17] Kim SH, Han DH, Choi GH, et al. Oncologic impact of lymph node dissection for intrahepatic cholangiocarcinoma: a propensity score-matched study[J]. J Gastrointest Surg, 2019, 23(3):538-544.
[18] Zhou R, Lu D, Li W, et al. Is lymph node dissection ne-cessary for resectable intrahepatic cholangiocarcinoma? a systematic review and meta-analysis[J]. HPB (Oxford), 2019, 21(7):784-792.
[19] Okami J, Dono K, Sakon M, et al. Patterns of regional lymph node involvementin intrahepatic cholangiocarcinoma of the left lobe[J]. J Gastrointest Surg, 2003, 7(7):850-856.
[20] Tsuji T, Hiraoka T, Kanemitsu K, et al. Lymphatic spreading pattern of intrahepatic cholangiocarcinoma[J]. Surgery, 2001, 129(4):401-407.
[21] Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7(5):52.
[22] Kang SH, Choi Y, Lee W, et al. Laparoscopic liver resection versus open liver resection for intrahepatic cholangiocarcinoma: 3-year outcomes of a cohort study with propensity score matching[J]. Surg Oncol, 2020, 33:63-69.
[23] Martin SP, Drake J, Wach MM, et al. Laparoscopic approach to intrahepatic cholangiocarcinoma is associated with an exacerbation of inadequate nodal staging[J]. Ann Surg Oncol, 2019, 26(6):1851-1857.
[24] Weimann A, Varnholt H, Schlitt HJ, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma[J]. Br J Surg, 2000, 87(9):1182-1187.
[25] Ghali P, Marotta PJ, Yoshida EM, et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience[J]. Liver Transpl, 2005, 11(11):1412-1416.
[26] Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4):1178-1188.
[27] Lunsford KE, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case series[J]. Lancet Gastroenterol Hepatol, 2018, 3(5):337-348.
[28] Yamamoto M, Takasaki K, Otsubo T, et al. Recurrence after surgical resection of intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Surg, 2001, 8(2):154-157.
[29] Doussot A, Gonen M, Wiggers JK, et al. Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models[J]. J Am Coll Surg, 2016, 223(3):493-505.
[30] Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J]. Ann Surg Oncol, 2016, 23(1):235-243.
[31] Si A, Li J, Xing X, et al. Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes[J]. Surgery, 2017, 161(4):897-908.
[32] Buettner S, Koerkamp BG, Ejaz A, et al. The effect of preoperative chemotherapy treatment in surgically treated 308 intrahepatic cholangiocarcinoma patients-a multi-institutional analysis[J]. J Surg Oncol, 2017, 115(3):312-318.
[33] Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7):839-847.
[34] Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J]. World J Surg, 2018, 42(9):2910-2918.
[35] Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metasta-tic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5):671-684.
[36] Javle M, Lowery M, Shroff RT, et al. Phase Ⅱ study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J]. J Clin Oncol, 2018, 36(3):276-282.
[37] Kim RD, Chung V, Alese OB, et al. A Phase 2 multi institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894.
[38] Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(8):611-621.
[39] Lin J, Yang X, Long J, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma[J]. Hepatobiliary Surg Nutr, 2020, 9(4):414-424.
Options
文章导航

/

〈 〉